Three investigative therapies by Proteostasis Therapeutics PTI-801, PTI-808, and PTI-428 showed potential to treat cystic fibrosis (CF) patients ineligible for approved CFTR modulators after patient-specific lab models produced promising results that support a future clinical trial.
Funded by the EUs initiative HIT-CF (Human Individualized Therapy of CF), this early study was conducted on patient organoids, which are miniaturized organ models derived from patient cells.
Based on the positive results, a clinical trial in adult CF patients is expected to start in 2020. If successful, the trial results may serve as the basis for a marketing authorization applicationin Europe in 2021.
With the help of CF-Europe (a patient organization) and the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN), HIT-CF has been recruiting adult CF patients to collect tissue samples and create organoids, three-dimensional organ models grown in the lab.
Organoids mimic several characteristics of the organ from which they are derived, and are genetically identical to the donor. As such, they allow researchers to study biological processes and response to treatments in an environment that closely resembles human organs. As organoids are basically human cells cultured outside the body, they are said to be ex-vivo models.
The idea is to screen treatment candidates in the lab using intestinal organoids, or mini-intestines, obtained from rectal tissue (biopsies) of patients, which are collected through a quick and painless procedure. Then, based on how the organoids respond to each therapeutic candidate, a group of patients will be selected to enroll in a clinical trial.
Because the organoids can help determine the therapeutic candidate most likely to give the best results, researchers can personalize treatments for each patient before starting the trial.
So far, intestinal organoids from more than 300 patients have been created, of which 65 have been used to test Proteostasis potential CFTR modulators.
Proteostasis is honored to have been invited to participate in the HIT-CF project, and is the only company in the group with a combination of novel CFTR modulators being testedex-vivo. We are very enthusiastic about the progress of the study, Geoffrey Gilmartin, MD, chief medical officer of Proteostasis, said in a press release.
The positive results obtained on organoids support the launch of a clinical trial called CHOICES Crossover trial based on HumanOrganoidIndividual response inCF EfficacyStudy that will test the potential treatments on patients whose organoids responded favorably to the agents.
The study will also evaluate if organoids are good models to identify promising CF therapies, that is, if the responses measured on organoids translate to potential clinical benefits in patients, as reflected by lung function tests (FEV1) or sweat tests.
CHOICES will be a placebo-controlled, double-blind study that includes an eight-week treatment period, plus six months of constant dosing.
The study includes Proteostasis three candidate CFTR modulators, specially intended for patients who carry rarer CFTR genetic defects. All three compounds have different modes of action. PTI-801 works as a CFTR corrector, PTI-808 is a CFTR potentiator, and PTI-428 is a CFTR amplifier.
The trial is planned to start in mid-2020, with its first data anticipated for the end of 2020.
If moving forward, CHOICES will become the first trial based on personalized medicine for CF patients.
The inequality in access to CFTR modulators is an acute problem across Europe where 1 in 5 individuals do not have a F508del mutation [the most common CF-causing mutation]. In addition, drug reimbursement policies are leading to an ever-growing gap between patients who do, and those who do not have effective treatment options, said Christiane De Boeck, Work Package Leader at HIT-CF.
At HIT-CF Europe, we believe that novel strategies such as personalized medicine and development of new treatment options are central to addressing the inequality of access across the continent. We are thrilled with these initial results and look forward to providing additional updates, De Boeck added.
Gilmartin said that in Europe more than 2,300 adult CF patients are ineligible for approved CFTR modulators, and therefore excluded from participating in clinical trials.
This projects proposed personalized medicine approach is paving a potential new way to develop and provide access to novel CFTR modulators for patients with the most dire need for treatment options that target the cause of the disease. Additionally, based on an individual patients disease phenotype, and not just the genetic designation, this approach could also create a new path towards more effective treatment for all people with CF, Gilmartin said.
Proteostasis is also running a clinical trial evaluating a combination of the three candidate therapies for the treatment of CF patients who have at least one copy of the F508del mutation in the CFTR gene.
Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.
Total Posts: 336
Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
Go here to read the rest:
- Myriad Announces Partnership with OptraHEALTH to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients - BioSpace - July 6th, 2020
- Children's National Medical Center and AWS partner for genome project targeting COVID-19 - SiliconANGLE - July 6th, 2020
- Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer - BioSpace - July 6th, 2020
- Movers & Shakers, July 3 | BioSpace - BioSpace - July 6th, 2020
- The Future of Medicine Is Bespoke - Fair Observer - July 6th, 2020
- July: Genome sequencing rare diseases | News and features - University of Bristol - July 6th, 2020
- Dropping Race-Based eGFR Adjustment Gains Traction in US - Medscape - July 6th, 2020
- A New Generation of Coronavirus Tests Is Coming. Here's What to Expect. - The New York Times - July 6th, 2020
- Fine-tuning brain activity reverses memory problems in mice with autism mutation - Spectrum - July 6th, 2020
- Male fruit flies' decline in fertility with age is not only driven by changes in sperm - Mirage News - July 6th, 2020
- In the Future, Lab Mice Will Live in Computer Chips, Not Cages - Medscape - July 6th, 2020
- For cancer treatment and more, genetic-based precision medicine holds a lot of promise - Connecticut Magazine - May 31st, 2020
- Drug factories: GMOs and gene editing are poised to transform medicine. Here's how. - Genetic Literacy Project - May 31st, 2020
- How to know your risk factors for hypertension and whether high blood pressure is genetic - Insider - INSIDER - May 31st, 2020
- Venture capital found its footing in biotech. Then came the virus. - BioPharma Dive - May 31st, 2020
- Israeli Lab: Drugs For Gaucher Disease May Work Against Coronavirus, Other Viral Infections | Health News - NoCamels - Israeli Innovation News - May 31st, 2020
- Rapid Growth on Genetic Testing Market with COVID-19 Impact Analysis, Top Key Companies like Abbott Laboratories Bio-Rad Laboratories Inc.,... - May 31st, 2020
- insideHPC Special Report: HPC and AI for the Era of Genomics - insideHPC - May 31st, 2020
- More insight into the cytokine storm caused by Covid-19 could lead to a treatment - Health24 - May 31st, 2020
- UCalgary researchers launch 360-degree study of children and COVID-19 - UCalgary News - May 31st, 2020
- 4000 Years of contact, conflict and cultural change had little genetic impact in Near East - University of Birmingham - May 31st, 2020
- Precision Medicine Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty - May 31st, 2020
- NOT REAL NEWS: A look at what didn't happen this week - wausaupilotandreview.com - May 31st, 2020
- Precision Medicine Informs Cost-Effective Heart Disease Treatments - HealthITAnalytics.com - May 19th, 2020
- Colonizing Mars may require humanity to tweak its DNA - Space.com - May 19th, 2020
- Complement genes add to sex-based vulnerability in lupus and schizophrenia - Newswise - May 19th, 2020
- 23andMe Is Trying to Crack the Genetic Code Behind the Coronavirus - Motley Fool - May 19th, 2020
- Global Molecular Diagnostics Industry 2019-2029: Genetic Disorders, Cardiovascular Disorders, Infections and Cancer - Yahoo Finance UK - May 19th, 2020
- Prominent Cancer Researcher to Join DRI and Renown Health - GlobeNewswire - May 19th, 2020
- Research Roundup: HIV vaccination, diabetes two-in-one injection, hybrid fish genetics - The Stanford Daily - May 19th, 2020
- Singapore researches discover specific gene linked to Asian Lung Cancer - BSA bureau - May 19th, 2020
- Grant will help scientists break new ground in gene editing - Newswise - May 19th, 2020
- Genomic Medicine Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Ingersoll Rand, Johnson Controls, Daikin, United... - May 19th, 2020
- Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic... - May 19th, 2020
- Coronavirus immunity passports could create a world of 'us and them'. But here's why they make sense - Genetic Literacy Project - May 19th, 2020
- New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair - SciTechDaily - May 19th, 2020
- Scientists race to find a cure or vaccine for the coronavirus. Here are the top drugs in development - CNBC - May 19th, 2020
- WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? - Byline Times - May 19th, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market Size, Share, Trends and Forecast 2026 by Major Players and Business Opportunities Caribou... - May 19th, 2020
- Researchers: Disease affecting kids could be in the genes - Newsday - May 19th, 2020
- From Competition To Sharing: How Her Childrens Rare Disease Led Sharon Terry To Revolutionize Medical Research - Forbes - May 9th, 2020
- Infection rates may have links to cancer - Medical News Today - May 9th, 2020
- Twin peeks: Stanford inherits twin registry, expanding research options - Stanford Medical Center Report - May 9th, 2020
- Management of Fertility and Hormonal Health in Women at Risk for Hereditary Gynecologic Cancers - Endocrinology Advisor - May 9th, 2020
- Individualized mosaics of microbial strains transfer from the maternal to the infant gut - Newswise - May 9th, 2020
- The Falsehoods of the 'Plandemic' Video - FactCheck.org - May 9th, 2020
- Its in your genes Whether Covid lands you in hospital or not depends on your body - ThePrint - May 9th, 2020
- FDA approves Tabrecta, first targeted therapy to treat metastatic NSCLC - The Cancer Letter - May 9th, 2020
- Research into the health of unborn babies receives government funding - UNSW Newsroom - May 9th, 2020
- Genetics and Weight: Is There an Obesity Gene? - LIVESTRONG.COM - May 9th, 2020
- New medical foundation invests in COVID-19 research funding - News - The University of Sydney - May 9th, 2020
- What Do Your Genetics Have to Do With Your Chances of Dying From Coronavirus? - Vanity Fair - May 3rd, 2020
- Scientists Find New Way to Inject Plants With Medicine, And It May Help Save Our Crops - ScienceAlert - May 3rd, 2020
- Sarepta Therapeutics Announces Research Agreement with US Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as... - May 3rd, 2020
- Evanston hospitals expand to antibody testing - The Daily Northwestern - May 3rd, 2020
- Profits and Pride at Stake, the Race for a Vaccine Intensifies - The New York Times - May 3rd, 2020
- Data On Thousands Of Twins Reveals How Genetics Influences Covid-19 Symptoms - IFLScience - May 3rd, 2020
- The pieces of the puzzle of covid-19s origin are coming to light - The Economist - May 3rd, 2020
- LIST: UW awards $2.2 million to groups, scientists fighting the coronavirus in Wisconsin - WMTV - May 3rd, 2020
- World Laughter Day 2020: Why we must remember that laughter is indeed the best medicine - Hindustan Times - May 3rd, 2020
- When COVID-19 Mutates, What Are the Risks? - MedicineNet - May 3rd, 2020
- Facts that China is trying to suppress about origin of COVID-19 - WION - May 3rd, 2020
- COVID-19: What's RNA research got to do with it? - University of Rochester - May 3rd, 2020
- Medical, tech investments pay off in Covid-19 war - The Straits Times - May 3rd, 2020
- Welcome to the kingdom of the sick - Salon - May 3rd, 2020
- Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection - CMAJ - May 3rd, 2020
- XBiotech Identifies Super Bloods for the Development of a True Human COVID-19 Therapy - GlobeNewswire - May 3rd, 2020
- On National DNA Day, scientists are trying to take the colonialism out of genetics - Massive Science - April 26th, 2020
- Turning On the 'Off Switch' in Cancer Cells - Michigan Medicine - April 26th, 2020
- Turkey's top scientific body invests TL 2.3 billion on 16 vaccine projects over 5 years | Daily Sabah - Daily Sabah - April 26th, 2020
- Covid-19 will pass. What about the racism it has illuminated? - STAT - April 26th, 2020
- Infection Rate May Indicate a Future Diagnosis of Cancer - Cancer Network - April 26th, 2020
- Misleading coronavirus information falsely attributed to Johns Hopkins - AFP Factcheck - April 26th, 2020
- He signed up for a coronavirus vaccine trial using a method that's never been used in humans. Here's why. - CNN - April 26th, 2020
- New study could lead to therapeutic interventions to treat cocaine addiction - Newswise - April 26th, 2020
- As Cuomo Issues New Executive Order, Weill Cornell Medicine Ramps Up COVID-19 Testing - Cornell University The Cornell Daily Sun - April 26th, 2020
- Another Step Towards Earlier Detection of Pancreatic Cancer - MedPage Today - April 26th, 2020
- UW president, biochemistry chair and mathematics professor named to American Academy of Arts and Sciences - UW News - April 26th, 2020
- Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked... - April 26th, 2020
- Childhood Psychopathology Linked to Higher Levels of Genetic Vulnerability of Adult Depression - Clinical OMICs News - April 26th, 2020